Predictive Technology Group, Inc. (PRED) Announces Completion of Genotyping in Two Clinical Trials of ARTGuide™
February 20, 2018 09:00 ET
|
PREDICTIVE TECHNOLOGY GROUP, INC.
SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK:PRED) announces that Predictive Therapeutics, LLC, its wholly-owned subsidiary, completed a crucial...
Earth Science Tech, Inc. Signs Agreement with TransBiotech to start in Vitro & in Vivo in Phase II for Nutraceutical Patents
November 14, 2017 08:00 ET
|
Earth Science Tech, Inc.
Doral, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of industrial hemp...
![Bob Woodruff Foundation](/news-release/logo/400605/0/400605.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A27&size=2)
Bob Woodruff Foundation Establishes Interim Funding for Injured Veteran IVF Services
October 18, 2016 09:08 ET
|
Bob Woodruff Foundation
NEW YORK, Oct. 18, 2016 (GLOBE NEWSWIRE) -- The Bob Woodruff Foundation celebrates the culmination of months of work by Congress and advocacy by multiple veteran serving organizations. Congressional...
Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy
May 16, 2016 08:01 ET
|
Fate Therapeutics, Inc.
Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota Program to be Presented Today at Innate Killer Summit 2016 SAN DIEGO, May 16,...
Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)
June 16, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that a new publication (June 2, 2014) in the Formulary Journal...
Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus
June 03, 2014 13:06 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon® N, inhibits...